Exploring the significance of caspase-cleaved tau in tauopathies and as a complementary pathology to phospho-tau in Alzheimer’s disease: implications for biomarker development and therapeutic targeting. The gene discussed is MAPT; the disease is early-onset autosomal dominant Alzheimer disease.